Hispanic Ethnicity is Associated with Milder Disease Severity in Crohn’s Disease but not Ulcerative Colitis
Journal Title: Current Trends in Gastroenterology and Hepatology - Year 2019, Vol 2, Issue 2
Abstract
Background: The incidence of inflammatory bowel disease (IBD) is rising among minority patients; however, few studies have examined racial/ethnic disparities in epidemiology, disease severity, and treatment course. Aim: To characterize differences in IBD disease severity and outcomes among IBD patients from minority communities. Methods: A cohort of adult patients with IBD was followed from January 2007- December 2012 in a large urban safety-net hospital. Fisher exact and Mann-Whitney rank sum tests were used to compare disease phenotype, severity, need for anti-TNF therapy, receipt of IBD-related surgery, and hospitalizations. Results: We identified 291 adult IBD patients; 148 with Crohn’s Disease (CD), 143 with ulcerative colitis (UC). Our cohort was racially diverse with 32% Caucasian, 37% Black, 28% Hispanic, and 2% Asian. 54% were male and the median age of the cohort was 44 years. Hispanic patients had a more benign disease course characterized by less IBD-related surgeries (mean 0.4 vs. 1.1, p=0.001), less hospitalizations (mean 2.1 vs. 2.9, p=0.04), and lower need for anti-TNF therapy (27% vs. 39%, p=0.05) when compared to non-Hispanic patients. On subgroup analysis, these differences were noted particularly among those with CD but not UC. Hispanic UC patients had a similar number of IBD-related surgeries (p=0.16) and hospitalizations (p=0.62), whereas Hispanic CD patients had less IBD-related surgeries (mean 0.8 vs. 1.8, p=0.01), less hospitalizations (mean 2.4 vs. 3.8, p=0.05), and lower need for anti-TNF (38% vs. 57%, p=0.09). Conclusion: Hispanic ethnicity is associated with lower disease severity in CD but not associated with disease severity in UC.
Authors and Affiliations
Christie Choi, Amit Singal, Kunjali Padhya, Avegail Flores, Ezra Burstein, Tasneem Ahmed
Keywords
Related Articles
- EP ID EP573133
- DOI 10.32474/CTGH.2019.02.000132
- Views 74
- Downloads 0
Rifaximin for Treatment of Small Bowel Bacterial Overgrowth
Small intestinal bacterial overgrowth (SIBO) is often secondary to intestinal dysmotility and several other predisposing conditions. Treatment of SIBO typically includes antibiotics and treatment of underlying etiology....
Hispanic Ethnicity is Associated with Milder Disease Severity in Crohn’s Disease but not Ulcerative Colitis
Background: The incidence of inflammatory bowel disease (IBD) is rising among minority patients; however, few studies have examined racial/ethnic disparities in epidemiology, disease severity, and treatment course. Aim:...
Description of Plasma Concentrations of Free Amino Acids with Some Clinical Symptoms of Patients Under 5 with Short Bowel Syndrome
Amino acid (AA) is the main component of proteins. Changes in levels of plasma AA concentration have been mentioned in some cases such as plasma AA concentrations in chronic kidney disease (CKD) patients are low when inf...
Advanced Hepatocellular Carcinoma in A Scottish Population – Current Experience and the Future
Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other drugs are emerging as efficacious agents in this setting. This article will outline our current...
Reflections About the Gut, A Microbiologist’s Perspective
Without doubt, the original function of the human gut was to digest and absorb food. Its epithelial cells absorb food after it has been processed to smaller components by enzymatic digestion. Comparable epithelial proces...